SNRPCP17: A Potential Drug Target and Biomarker (G106481702)

Target Name: SNRPCP17

NCBI ID: G106481702

SNRPCP17

Other Name(s): small nuclear ribonucleoprotein polypeptide C pseudogene 17 | Small nuclear ribonucleoprotein polypeptide C pseudogene 17

SNRPCP17: A Potential Drug Target and Biomarker

Small nuclear ribonucleoprotein (SNRNP) pseudogenes are a group of non-coding RNAs that resemble the protein coding regions of SNRNPs but lack the ability to synthesize proteins. SNRPCP17 is one of the most well-studied SNRNP pseudogenes. This gene has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

History of SNRPCP17 Research

The study of SNRPCP17 began in the late 1990s, when researchers identified a potential SNRNP gene in the human genome. Since then, numerous studies have investigated the functions and potential uses of this gene.

One of the early studies identified a potential RNA binding site in the SNRPCP17 gene that could interact with small nucleolar RNA (snRNA) species. This interaction between the gene and snRNA species suggested that SNRPCP17 may play a role in regulating gene expression and that it may be a potential drug target.

Subsequent studies have also shown that SNRPCP17 can interact with various protein factors, including histone modifications and non-coding RNAs. These interactions further supported the idea that SNRPCP17 is involved in gene regulation and that it may be a potential drug target.

Potential Functions as a Drug Target

SNRPCP17 has been shown to play a role in various cellular processes, including cell growth, apoptosis, and inflammation. It has also been shown to interact with various proteins and RNA species, which suggests that it may be involved in the regulation of gene expression and protein synthesis.

One of the potential functions of SNRPCP17 as a drug target is its role in cancer progression. Studies have shown that SNRPCP17 can be overexpressed in various cancer types, including breast, ovarian, and colorectal cancers. This overexpression is associated with poor prognosis and increased tumor burden.

In addition to its role in cancer, SNRPCP17 has also been shown to contribute to neurodegenerative diseases. Studies have shown that SNRPCP17 can be overexpressed in various neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. This overexpression is associated with increased neurofibrillary tangles and decreased protein levels, which are hallmarks of neurodegenerative diseases.

Potential as a Biomarker

SNRPCP17 has also been shown to be a potential biomarker for various diseases. For example, studies have shown that SNRPCP17 can be used as a biomarker for cancer, as the expression of SNRPCP17 is often altered in cancer cells compared to normal cells.

In addition to its potential as a drug target, SNRPCP17 has also been shown to be a potential biomarker for neurodegenerative diseases. The overexpression of SNRPCP17 in neurodegenerative diseases is associated with increased neurofibrillary tangles and decreased protein levels, which are hallmarks of these diseases.

Conclusion

SNRPCP17 is a well-studied SNRNP pseudogene that has been shown to play a role in various cellular processes, including cell growth, apoptosis, and inflammation. It has also been shown to interact with various proteins and RNA species, which suggests that it may be involved in the regulation of gene expression and protein synthesis.

In addition to its potential as a drug target, SNRPCP17 has also been shown to be a potential biomarker for various diseases, including cancer and neurodegenerative diseases. Further research is needed to fully understand the functions and potential uses of SNRPCP17, including its potential as a drug

Protein Name: Small Nuclear Ribonucleoprotein Polypeptide C Pseudogene 17

The "SNRPCP17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNRPCP17 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets